Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635978 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL17024449 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL25498781 | 0.81 | HTR2C (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL16903465 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL16903468 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL19635977 | 0.77 | PDE4B (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL18340933 | 0.75 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL2502213 | 0.75 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL2146179 | 0.75 | HTR2C (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C | |
| SCHEMBL206806 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565323-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | Rappta Therapeutics Oy (FI) | 2025-06-11 | — | — | EP | disclosed |
| CN-119968358-A | Protein phosphatase 2A (PP 2A) modulators and methods of use thereof | 拉普他治疗公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024028808-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | RAPPTA THERAPEUTICS OY (FI) | 2024-02-08 | — | — | WO | disclosed |
| EP-3708165-B1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SINOMAB BIOSCIENCE LTD (CN) | 2023-01-18 | — | — | EP | disclosed |
| EP-3459940-B1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SUZHOU SINOVENT PHARMACEUTICALS CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | SINOMAB BIOSCIENCE LIMITED (HK) | 2021-11-23 | — | — | US | disclosed |
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | SUZHOU SINOVENT PHARMA CO., LTD. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3708165-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | Sinomab Bioscience Limited (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3459940-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Zhejiang Yukon Pharma Co., Ltd. (CN) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198050-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | 浙江予川医药科技有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882843-B2 | 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof | BTK, SYK, LCK | SMN1; SMN2 4637/4885NPC1 4331/4885RAB9A 2771/4885 |
| US-20200361902-A1 | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS BTK INHIBITOR | BTK, SYK, LCK | SMN1; SMN2 4806/4885NPC1 4532/4885RAB9A 2323/4885 |
| US-11180475-B2 | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor | BTK, SYK, LCK | SMN1; SMN2 4806/4885NPC1 4532/4885RAB9A 2323/4885 |
| US-20190152952-A1 | 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | BTK, SYK, LCK | SMN1; SMN2 4637/4885NPC1 4331/4885RAB9A 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.